0001209191-19-060476.txt : 20191213
0001209191-19-060476.hdr.sgml : 20191213
20191213173550
ACCESSION NUMBER: 0001209191-19-060476
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20191212
FILED AS OF DATE: 20191213
DATE AS OF CHANGE: 20191213
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: YANG MICHAEL J.
CENTRAL INDEX KEY: 0001702283
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-50768
FILM NUMBER: 191285397
MAIL ADDRESS:
STREET 1: C/O ACADIA PHARMACEUTICALS INC.
STREET 2: 3611 VALLEY CENTRE DRIVE,SUITE 300
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ACADIA PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001070494
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 061376651
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3611 VALLEY CENTRE DRIVE
STREET 2: SUITE 300
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: 858-558-2871
MAIL ADDRESS:
STREET 1: 3611 VALLEY CENTRE DRIVE
STREET 2: SUITE 300
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-12-12
0
0001070494
ACADIA PHARMACEUTICALS INC
ACAD
0001702283
YANG MICHAEL J.
C/O ACADIA PHARMACEUTICALS INC.
3611 VALLEY CENTRE DRIVE, STE. 300
SAN DIEGO
CA
92130
0
1
0
0
EVP and CCO
Common Stock
2019-12-12
4
M
0
22500
19.98
A
24999
D
Common Stock
2019-12-12
4
M
0
10000
21.28
A
34999
D
Common Stock
2019-12-12
4
M
0
72979
35.86
A
107978
D
Common Stock
2019-12-12
4
S
0
100447
44.493
D
7531
D
Common Stock
2019-12-12
4
S
0
5032
43.735
D
2499
D
Stock Option (Right to Buy)
19.98
2019-12-12
4
M
0
22500
0.00
D
2028-04-17
Common Stock
22500
577500
D
Stock Option (Right to Buy)
21.28
2019-12-12
4
M
0
10000
0.00
D
2028-10-14
Common Stock
10000
30000
D
Stock Option (Right to Buy)
35.86
2019-12-12
4
M
0
72979
0.00
D
2027-03-28
Common Stock
72979
312500
D
Includes 876 shares of the Issuer's common stock acquired by the reporting person on November 15, 2017 pursuant to an employee stock purchase program.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 6, 2019.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.755 to $44.75, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.67 to $43.75, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
25% of the 600,000 shares originally subject to the Stock Option vested and became exercisable on April 18, 2019. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments
25% of the 40,000 shares originally subject to the Stock Option vested and became exercisable on October 15, 2019. The remaining shares vest and become excercisable thereafter in 36 equal monthly installments.
25% of the 400,000 shares originally subject to the stock option vested and became exercisable on March 29, 2018. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments.
/s/ Austin D. Kim, Attorney-in-Fact
2019-12-13